Vanguard Group
LBRX

Vanguard Group’s LB Pharmaceuticals LBRX Stock Holding History

Vanguard Group’s Portfolio LBRX Stock Details LBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$24.8M Buy
+1,112,978
New +$19.4M ﹤0.01% 2523

Other funds holding LBRX

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
SSC
Spruce Street Capital New York $416M AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Vanguard Group's LBRX Position: Q4 2025 in Review

Vanguard Group opened a new position in LB Pharmaceuticals (LBRX) in Q4 2025: 1,112,978 shares worth $24.8M. The stake represents ﹤0.01% of the portfolio and ranks #2523 among its holdings.

68 funds tracked by Wall St. Rank hold LBRX as of Q4 2025.

  • Vanguard Group held 1,112,978 shares of LB Pharmaceuticals worth $24.8M as of Q4 2025.
  • LB Pharmaceuticals was a new Vanguard Group position in Q4 2025.
  • LB Pharmaceuticals made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #2523 holding.
  • 68 funds tracked by Wall St. Rank held LB Pharmaceuticals as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.